Ocugen
Nasdaq OCGN · Malvern, PA
Works in Genetic & rare · Immunology · Infectious disease · Ophthalmology · Respiratory
Ocugen is a clinical trial sponsor based in Malvern, PA, listed as Nasdaq OCGN. It has 6 active clinical trials with 534 planned participants, across 5 therapeutic areas. Since 2021 it has completed 2 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq OCGN
Fundraising
Pipeline · 6 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Ocugen
Ocugen is lead sponsor of 6 active clinical trials on ClinicalTrials.gov, with 534 planned participants, in Genetic & rare, Immunology, Infectious disease, Ophthalmology and other areas. Since 2021 it has completed 2 trials and stopped 1 early.
Ocugen is based in Malvern, PA and is listed as Nasdaq OCGN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Ocugen; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-02.
Approve Suite is not affiliated with Ocugen.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.